Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 2084  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

    Article Cited by others


Orphan drug: Development trends and strategies

Sharma Aarti, Jacob Abraham, Tandon Manas, Kumar Dushyant

Year : 2010| Volume: 2| Issue : 4 | Page no: 290-299

   This article has been cited by
1 Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan
Chun-Ming Liao, Wei-Yin Kuo, Pei-Tseng Kung, Chuang-Hui Chuan, Wen-Chen Tsai
Multiple Sclerosis Journal. 2022; : 1352458521
[Pubmed]  [Google Scholar] [DOI]
2 Who funds Alzheimer's disease drug development?
Jeffrey Cummings, Justin Bauzon, Garam Lee
Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2021; 7(1)
[Pubmed]  [Google Scholar] [DOI]
3 Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
Marije E. Hagendijk, Simon van der Schans, Cornelis Boersma, Maarten J. Postma, Simon van der Pol
The European Journal of Health Economics. 2021; 22(6): 991
[Pubmed]  [Google Scholar] [DOI]
4 Current and Emerging Clinical Treatment in Mitochondrial Disease
Rory J. Tinker, Albert Z. Lim, Renae J. Stefanetti, Robert McFarland
Molecular Diagnosis & Therapy. 2021; 25(2): 181
[Pubmed]  [Google Scholar] [DOI]
5 An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020
Shuhang Wang, Qiuyan Yang, Lan Deng, Qi Lei, Yuqi Yang, Peiwen Ma, Yuxin Men, Bryant C. Yung, Robert J. Lee, Mengzi Zhang, Ning Li
Drug Discovery Today. 2021;
[Pubmed]  [Google Scholar] [DOI]
6 A Comparative Study of Pharmaceutical Incentives to Patents in India, USA and Europe
Renu Kadian, Arun Nanda
Applied Drug Research, Clinical Trials and Regulatory Affairs. 2021; 8(1): 12
[Pubmed]  [Google Scholar] [DOI]
7 Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis
Adrienne Y.L. Chan, Vivien K.Y. Chan, Sten Olsson, Min Fan, Mark Jit, Mengchun Gong, Shuyang Zhang, Mengqin Ge, Swathi Pathadka, Claudia C.Y. Chung, Brian H.Y. Chung, Celine S.L. Chui, Esther W. Chan, Gloria H.Y. Wong, Terry Y. Lum, Ian C.K. Wong, Patrick Ip, Xue Li
Value in Health. 2020; 23(12): 1580
[Pubmed]  [Google Scholar] [DOI]
8 A survey of critical care pharmacists to patient ratios and practice characteristics in intensive care units
Andrea S. Newsome, Susan E. Smith, Timothy W. Jones, Ashley Taylor, Megan A. Van Berkel, Marina Rabinovich
[Pubmed]  [Google Scholar] [DOI]
9 Exploring different approaches to improve the success of drug discovery and development projects: a review
Geoffrey Kabue Kiriiri, Peter Mbugua Njogu, Alex Njoroge Mwangi
Future Journal of Pharmaceutical Sciences. 2020; 6(1)
[Pubmed]  [Google Scholar] [DOI]
10 Challenges in orphan drug development and regulatory policy in China
Alice Cheng,Zhi Xie
Orphanet Journal of Rare Diseases. 2017; 12(1)
[Pubmed]  [Google Scholar] [DOI]
11 Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
Lieven Annemans,Ségolčne Aymé,Yann Le Cam,Karen Facey,Penilla Gunther,Elena Nicod,Michele Reni,Jean-Louis Roux,Michael Schlander,David Taylor,Carlo Tomino,Josep Torrent-Farnell,Sheela Upadhyaya,Adam Hutchings,Lugdivine Le Dez
Orphanet Journal of Rare Diseases. 2017; 12(1)
[Pubmed]  [Google Scholar] [DOI]
12 Using phase II data for the analysis of phase III studies: An application in rare diseases
Simon Wandel,Beat Neuenschwander,Christian Röver,Tim Friede
Clinical Trials. 2017; 14(3): 277
[Pubmed]  [Google Scholar] [DOI]
13 Accelerated Access to Medicines
Jessica Pace,Narcyz Ghinea,Ian Kerridge,Wendy Lipworth
Therapeutic Innovation & Regulatory Science. 2017; 51(2): 157
[Pubmed]  [Google Scholar] [DOI]
14 Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials
Stefan Anzelewicz,Hanna Garnier,Arun Rangaswami,Piotr Czauderna
Expert Opinion on Orphan Drugs. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
15 Promoting innovation and access to quality, safe, efficacious, and affordable medicines for children: A China approach on the 69th World Health Assembly
Lingli Zhang,Bo Li,Zhanqiang Liu,Mengtao Li,Hong Zheng,Yang Sun
Journal of Evidence-Based Medicine. 2017; 10(2): 70
[Pubmed]  [Google Scholar] [DOI]
16 Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model
Matthew I. Bellgard,Kathryn R. Napier,Alan H. Bittles,Jeffrey Szer,Sue Fletcher,Nikolajs Zeps,Adam A. Hunter,Jack Goldblatt
Blood Cells, Molecules, and Diseases. 2017;
[Pubmed]  [Google Scholar] [DOI]
17 New concepts on the therapeutic control of complement anaphylatoxin receptors
Owen A. Hawksworth,Xaria X. Li,Liam G. Coulthard,Ernst J. Wolvetang,Trent M. Woodruff
Molecular Immunology. 2017;
[Pubmed]  [Google Scholar] [DOI]
18 “Good news is not always a positive market signal”—Investors activity around orphan drug designation
Tiran Rothman
Economics Letters. 2017;
[Pubmed]  [Google Scholar] [DOI]
19 Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea
Sun-Young Park,Euna Han,Jini Kim,Eui-Kyung Lee
Health Policy. 2016;
[Pubmed]  [Google Scholar] [DOI]
20 A review of the progress and pitfalls of FDA policy process: Planning a pathway for pharmaceutical interventions for hearing loss development
Tanisha L. Hammill
Hearing Research. 2016;
[Pubmed]  [Google Scholar] [DOI]
21 Pain in an era of armed conflicts: Prevention and treatment for warfighters and civilian casualties
E. George,I. Elman,L. Becerra,Sheri Berg,D. Borsook
Progress in Neurobiology. 2016;
[Pubmed]  [Google Scholar] [DOI]
22 A Single-use Strategy to Enable Manufacturing of Affordable Biologics
Renaud Jacquemart,Melissa Vandersluis,Mochao Zhao,Karan Sukhija,Navneet Sidhu,Jim Stout
Computational and Structural Biotechnology Journal. 2016;
[Pubmed]  [Google Scholar] [DOI]
23 Static and Dynamic Properties of Fluorinated 4-Aryl-1,5-Benzodiazepinones
Olga Martín,Marta Pérez-Torralba,M. Ángeles García,Rosa M. Claramunt,M. Carmen Torralba,M. Rosario Torres,Ibon Alkorta,José Elguero
ChemistrySelect. 2016; 1(4): 861
[Pubmed]  [Google Scholar] [DOI]
24 A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy
Jiayi Huang,Jian L. Campian,Amit D. Gujar,David D. Tran,A. Craig Lockhart,Todd A. DeWees,Christina I. Tsien,Albert H. Kim
Journal of Neuro-Oncology. 2016;
[Pubmed]  [Google Scholar] [DOI]
25 Quantifying the persisting orphan-drug shortage public health crisis in the United States
Szymon Jaroslawski,Chiraz Azaiez,Daria Korchagina,Mondher Toumi
Journal of Market Access & Health Policy. 2016; : 1269473
[Pubmed]  [Google Scholar] [DOI]
26 Orphan Drugs and Potential Novel Approaches for Therapies of ß-Thalassemia: Current Status and Future Expectations
Alessia Finotti,Monica Borgatti,Nicoletta Bianchi,Cristina Zuccato,Ilaria Lampronti,Roberto Gambari
Expert Opinion on Orphan Drugs. 2016; 4(3): 299
[Pubmed]  [Google Scholar] [DOI]
27 Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in Japan
Shoyo Shibata,Ryotaro Uemura,Takeshi Suzuki
Therapeutic Innovation & Regulatory Science. 2016; 50(1): 56
[Pubmed]  [Google Scholar] [DOI]
28 In Vitro Screening for Drug Repositioning
Graeme F. Wilkinson,Kevin Pritchard
Journal of Biomolecular Screening. 2015; 20(2): 167
[Pubmed]  [Google Scholar] [DOI]
29 Effectiveness, safety and costs of orphan drugs: an evidence-based review
Igho J Onakpoya,Elizabeth A Spencer,Matthew J Thompson,Carl J Heneghan
BMJ Open. 2015; 5(6): e007199
[Pubmed]  [Google Scholar] [DOI]
30 Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
Todd Gammie,Christine Y. Lu,Zaheer Ud-Din Babar,Silvio Garattini
PLOS ONE. 2015; 10(10): e0140002
[Pubmed]  [Google Scholar] [DOI]
31 Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Pengfei Jiang,Rajesh Mukthavavam,Ying Chao,Ila Bharati,Valentina Fogal,Sandra Pastorino,Xiuli Cong,Natsuko Nomura,Matt Gallagher,Taher Abbasi,Shireen Vali,Sandeep C Pingle,Milan Makale,Santosh Kesari
Journal of Translational Medicine. 2014; 12(1): 13
[Pubmed]  [Google Scholar] [DOI]
32 Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Adam Hutchings,Carina Schey,Richard Dutton,Felix Achana,Karolina Antonov
Orphanet Journal of Rare Diseases. 2014; 9(1): 22
[Pubmed]  [Google Scholar] [DOI]
33 The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases
Kristina Sachs-Barrable,Jocelyn Conway,Pavel Gershkovich,Fady Ibrahim,Kishor M. Wasan
Drug Development and Industrial Pharmacy. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
34 A novel approach to sterile pharmaceutical freeze-drying
Christopher Lee Albert Cherry,Huw Millward,Rose Cooper,John Landon
Pharmaceutical Development and Technology. 2013; : 1
[Pubmed]  [Google Scholar] [DOI]
35 Benefits of investment into modern medicines in Central–Eastern European countries
András Inotai,Guenka Petrova,Dinko Vitezic,Zoltán Kaló
Expert Review of Pharmacoeconomics & Outcomes Research. 2013; : 1
[Pubmed]  [Google Scholar] [DOI]
36 Product lifecycle management through patents and regulatory strategies
Vandana Prajapati,Swagat Tripathy,Harish Dureja
Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing. 2013; 13(3): 171
[Pubmed]  [Google Scholar] [DOI]
37 Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Joachim Y. Doua,Jean-Pierre Van Geertruyden
Tropical Medicine & International Health. 2013; : n/a
[Pubmed]  [Google Scholar] [DOI]
38 Orphan drugs: the regulatory environment
Pedro Franco
Drug Discovery Today. 2013; 18(3-4): 163
[Pubmed]  [Google Scholar] [DOI]
39 Financing drug discovery for orphan diseases
David E. Fagnan,Austin A. Gromatzky,Roger M. Stein,Jose-Maria Fernandez,Andrew W. Lo
Drug Discovery Today. 2013;
[Pubmed]  [Google Scholar] [DOI]
40 When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada
Matthew Herder
Accountability in Research. 2013; 20(4): 227
[Pubmed]  [Google Scholar] [DOI]
41 Lipid Control in the Modern Era
Richard V. Milani,Carl J. Lavie
Journal of the American College of Cardiology. 2013; 62(23): 2185
[Pubmed]  [Google Scholar] [DOI]
42 Providing Medical Information for Orphan Drugs
Sean Turbeville,David A. Wells,Carl S. Hornfeldt
Drug Information Journal. 2012; 46(1): 88
[Pubmed]  [Google Scholar] [DOI]
43 Optimizing efficacy of mucosal vaccines
Ayman Gebril,Manal Alsaadi,Reinaldo Acevedo,Alexander B Mullen,Valerie A Ferro
Expert Review of Vaccines. 2012; 11(9): 1139
[Pubmed]  [Google Scholar] [DOI]
44 Orphan/rare drug discovery through drug repositioning
Ramaiah Muthyala
Drug Discovery Today: Therapeutic Strategies. 2011; 8(3-4): 71
[Pubmed]  [Google Scholar] [DOI]


Read this article